Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

NCT00375661 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: interferon-alfa-2b and ribavirin

Sponsor

Kyoto University